CME Group price target raised to $300 from $282 at Oppenheimer

Oppenheimer raised the firm’s price target on CME Group (CME) to $300 from $282 and keeps an Outperform rating on the shares. The firm says that CME’s April and May monthly data showed higher than expected trading volume in interest rates, equities, and energy. But, average rolling 3-month rate per contract in April was slightly lower than expected. Oppenheimer believes the main driver of this volatility and hedging activities is the uncertain tariff policy, which will likely continue in the near term. Additionally, there is an increasing concern on U.S. budget deficit as the one “big beautiful bill” would add $2.3T of debt over the next decade as estimated by CBO.